Jim Simons Eloxx Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.15 - $7.2 $6,885 - $330,480	-45,900 Reduced 25.59%	133,500 $23,000
Q2 2022 Aug 12, 2022	BUY	$0.24 - $0.58 $43,056 - $104,052	179,400 New	179,400 $48,000
Q3 2021 Nov 12, 2021	SELL	$1.22 - $2.0 $199,958 - $327,800	-163,900 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$1.35 - $3.36 $221,265 - $550,704	163,900 New	163,900 $326,000
Q1 2021 May 13, 2021	SELL	$3.02 - $4.54 $119,993 - $180,387	-39,733 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$2.42 - $4.48 $47,916 - $88,704	-19,800 Reduced 33.26%	39,733 $158,000
Q3 2020 Nov 13, 2020	SELL	$2.53 - $3.4 $77,924 - $104,720	-30,800 Reduced 34.1%	59,533 $157,000
Q2 2020 Aug 13, 2020	SELL	$1.56 - $3.65 $63,144 - $147,741	-40,477 Reduced 30.94%	90,333 $274,000
Q1 2020 May 14, 2020	SELL	$1.96 - $7.96 $11,172 - $45,372	-5,700 Reduced 4.18%	130,810 $256,000
Q4 2019 Feb 13, 2020	BUY	$3.19 - $7.56 $370,678 - $878,472	116,200 Added 572.13%	136,510 $1.01 Million
Q3 2019 Nov 13, 2019	BUY	$4.37 - $9.91 $88,754 - $201,272	20,310 New	20,310 $92,000

Ticker ELOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,656,200
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis p...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.